Navigation Links
Neurocrine Biosciences Announces the Start of Second Phase III Study of Elagolix in Endometriosis
Date:8/29/2013

but are not limited to, risk that elagolix will not proceed to later stage clinical trials for uterine fibroids; risk that the elagolix clinical trials will fail to demonstrate that elagolix is safe and effective for the treatment of uterine fibroids; risk that elagolix uterine fibroid Phase III clinical trials will be delayed or not successfully initiated; risk that elagolix Phase III clinical trials will fail to demonstrate that elagolix is safe and effective for the treatment of endometriosis; risk associated with the Company's dependence on corporate collaborators for clinical development, commercial manufacturing and marketing and sales activities. With respect to its pipeline overall, the Company faces risk that it will be unable to raise additional funding required to complete development of all of its product candidates; risk relating to the Company's dependence on contract manufacturers for clinical drug supply; risks associated with the Company's dependence on corporate collaborators for commercial manufacturing and marketing and sales activities; uncertainties relating to patent protection and intellectual property rights of third parties; risks and uncertainties relating to competitive products and technological changes that may limit demand for the Company's products; and the other risks described in the Company's report on Form 10-K for the year ended December 31, 2012 and report on Form 10-Q for the quarter ended June 30, 2013. Neurocrine undertakes no obligation to update the statements contained in this press release after the date hereof.


'/>"/>
SOURCE Neurocrine Biosciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Neurocrine Biosciences to Present at the Jefferies 2013 Global Healthcare Conference
2. Neurocrine Biosciences to Present At The Deutsche Bank 38th Annual dbAccess Health Care Conference
3. Neurocrine Biosciences Reports First Quarter 2013 Results
4. Neurocrine Biosciences to Present at the Needham 12th Annual Healthcare Conference
5. Neurocrine Biosciences Announces the Start of Phase IIb Study of Elagolix in Uterine Fibroids
6. Neurocrine Biosciences To Present At The 25th Annual Roth Conference
7. Neurocrine Biosciences To Present At The Cowen And Company 33rd Annual Health Care Conference
8. Neurocrine Biosciences To Present At The Leerink Swann Global Healthcare Conference 2013
9. Neurocrine Biosciences Announces Conference Call And Webcast To Present Fourth Quarter And Year-End 2012 Financial Results
10. Neurocrine Biosciences Announces Additional European And United States Patents Issued On Proprietary VMAT2 Inhibitor
11. Neurocrine Biosciences To Present At Deutsche Banks 2012 dbAccess BioFEST
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... September 22, 2014 According ... Development Market by Product (Equipment, Media and Reagents), by ... & Regenerative medicine, Toxicity Testing, Research, Drug Discovery) ... by MarketsandMarkets, analyzes and studies the major market ... Browse 114 market data tables and 64 figures ...
(Date:9/22/2014)... 22, 2014 Research and Markets  has ... Diclofenac Industry Report 2014" report to their offering. ... Report 2014 is a professional and in-depth study on ... a focus on the Chinese situation. The ... definitions, classifications, applications and industry chain structure. The diclofenac ...
(Date:9/22/2014)... , Sept. 22, 2014 CytRx Corporation ... development company specializing in oncology, today announced that study ... clinical trials of aldoxorubicin, a pivotal global Phase 3 ... a global Phase 2b clinical trial in small cell ... for Medical Oncology (ESMO) 2014 Congress being held September ...
Breaking Medicine Technology:Cell Line Development Market Worth $3.96 Billion by 2019 2Cell Line Development Market Worth $3.96 Billion by 2019 3Cell Line Development Market Worth $3.96 Billion by 2019 4Global and Chinese Diclofenac Industry Report 2014 2CytRx Announces Presentation of Aldoxorubicin Global Phase 3 Soft Tissue Sarcomas and Global Phase 2b Small Cell Lung Cancer Trial Designs at ESMO 2014 Congress 2CytRx Announces Presentation of Aldoxorubicin Global Phase 3 Soft Tissue Sarcomas and Global Phase 2b Small Cell Lung Cancer Trial Designs at ESMO 2014 Congress 3CytRx Announces Presentation of Aldoxorubicin Global Phase 3 Soft Tissue Sarcomas and Global Phase 2b Small Cell Lung Cancer Trial Designs at ESMO 2014 Congress 4CytRx Announces Presentation of Aldoxorubicin Global Phase 3 Soft Tissue Sarcomas and Global Phase 2b Small Cell Lung Cancer Trial Designs at ESMO 2014 Congress 5CytRx Announces Presentation of Aldoxorubicin Global Phase 3 Soft Tissue Sarcomas and Global Phase 2b Small Cell Lung Cancer Trial Designs at ESMO 2014 Congress 6
(Date:9/22/2014)... 22, 2014 Oregon Governor John ... as “Oregon Chiropractic Health and Wellness Month.” , ... (UWS) celebrates 110 years of leadership in educating ... was the first educational institution offering a doctor ... expanded over the past 110 years and now ...
(Date:9/22/2014)... Jose, California (PRWEB) September 22, 2014 ... Respiratory care market occupies a significant presence in ... the most widespread healthcare problems globally. Key factors ... unhealthy lifestyle habits such as smoking; increasing levels ... COPD; and expanding base of aging population vulnerable ...
(Date:9/22/2014)... The Spa Standard, announced today that Jenny ... in developing content and courses for their online social ... 15 years of experience in massage therapy, esthetics, day ... companies including Orient Express Hotels and the Capella Hotel ... Jenny gained extensive industry insight through planning, staffing, training ...
(Date:9/22/2014)... 22, 2014 The American Association for Thoracic ... the prevention and treatment of perioperative and postoperative ... procedures. The guidelines are published in The ... "These guidelines have the potential to prevent the ... who undergo lung surgery in the United States ...
(Date:9/22/2014)... can enhance the ability of the bacterium Streptococcus ... to research published ahead of print in the journal ... study, the investigators infected mice with either influenza alone, ... the populations of bacteria and virus over time. They ... infection. , Influenza infection enhanced the bacterium,s ability ...
Breaking Medicine News(10 mins):Health News:Oregon Governor Proclaims October as “Chiropractic Month” – UWS Brought Chiropractic Health Care to Oregon in 1904 2Health News:Rising Incidence of Respiratory Diseases to Drive the Respiratory Care Equipment and Supplies Market, According to New Report by Global Industry Analysts, Inc. 2Health News:Rising Incidence of Respiratory Diseases to Drive the Respiratory Care Equipment and Supplies Market, According to New Report by Global Industry Analysts, Inc. 3Health News:Rising Incidence of Respiratory Diseases to Drive the Respiratory Care Equipment and Supplies Market, According to New Report by Global Industry Analysts, Inc. 4Health News:The Spa Standard Appoints Vice-President of Content and Course Development 2Health News:New guidelines issued for managing peri- and postoperative atrial fibrillation 2Health News:New guidelines issued for managing peri- and postoperative atrial fibrillation 3Health News:New guidelines issued for managing peri- and postoperative atrial fibrillation 4Health News:Influenza A potentiates pneumococcal co-infection: New details emerge 2
... ... ... ... ...
... ... ... ... ...
... , ... ... ... ...
... ... custom stress balls has started 2010 with two record months which points to an economic ... ... balls has started 2010 with two record months which points to an economic upturn ...
... ctp ... this means for leadership and how it is redefining our understanding of soft skills. ... – all leading to better organisations and higher returns on human investment. , ... (PRWEB) March 2, 2010 ...
... Clinically Relevant Technologies ... management guidelines with the release of new medical iPhone app. , ... (PRWEB) March 2, 2010 -- Clinically Relevant Technologies released a new ... care gap. The release comes on the heels of a study published last month in ...
Cached Medicine News:Health News:MAP Pharmaceuticals Reports 2009 Fourth Quarter and Year End Financial Results 2Health News:MAP Pharmaceuticals Reports 2009 Fourth Quarter and Year End Financial Results 3Health News:MAP Pharmaceuticals Reports 2009 Fourth Quarter and Year End Financial Results 4Health News:MAP Pharmaceuticals Reports 2009 Fourth Quarter and Year End Financial Results 5Health News:MAP Pharmaceuticals Reports 2009 Fourth Quarter and Year End Financial Results 6Health News:MAP Pharmaceuticals Reports 2009 Fourth Quarter and Year End Financial Results 7Health News:MAP Pharmaceuticals Reports 2009 Fourth Quarter and Year End Financial Results 8Health News:MAP Pharmaceuticals Reports 2009 Fourth Quarter and Year End Financial Results 9Health News:MAP Pharmaceuticals Reports 2009 Fourth Quarter and Year End Financial Results 10Health News:MAP Pharmaceuticals Reports 2009 Fourth Quarter and Year End Financial Results 11Health News:MAP Pharmaceuticals Reports 2009 Fourth Quarter and Year End Financial Results 12Health News:MAP Pharmaceuticals Reports 2009 Fourth Quarter and Year End Financial Results 13Health News:MAP Pharmaceuticals Reports 2009 Fourth Quarter and Year End Financial Results 14Health News:Dental Operatory Equipment and Practice Management Software Market in the U.S. to Reach Almost $2 Billion by 2016 2Health News:Dental Operatory Equipment and Practice Management Software Market in the U.S. to Reach Almost $2 Billion by 2016 3Health News:Dental Operatory Equipment and Practice Management Software Market in the U.S. to Reach Almost $2 Billion by 2016 4Health News:Archimedes Pharma Announces Major Fund Raising of GBP65 Million 2Health News:Archimedes Pharma Announces Major Fund Raising of GBP65 Million 3Health News:Archimedes Pharma Announces Major Fund Raising of GBP65 Million 4Health News:Archimedes Pharma Announces Major Fund Raising of GBP65 Million 5Health News:Archimedes Pharma Announces Major Fund Raising of GBP65 Million 6Health News:Archimedes Pharma Announces Major Fund Raising of GBP65 Million 7Health News:Archimedes Pharma Announces Major Fund Raising of GBP65 Million 8Health News:Archimedes Pharma Announces Major Fund Raising of GBP65 Million 9Health News:Archimedes Pharma Announces Major Fund Raising of GBP65 Million 10Health News:Archimedes Pharma Announces Major Fund Raising of GBP65 Million 11Health News:Archimedes Pharma Announces Major Fund Raising of GBP65 Million 12Health News:Promotional Stress Ball Supplier -- StressBallsUK.com Starts 2010 Strongest Ever 2Health News:Key Leadership Seminar: Maximizing Profit through Social Intelligence - What Neuroscience Tells Us 2Health News:Clinically Relevant Technologies Releases New Medical iPhone App To Fill Gap In Adherence To Low Back Pain Management Guidelines 2
... Introduction of the Selenia full ... beginning of a new era in ... of elegance and innovation combines the ... with sophisticated information management capabilities to ...
... The Stellate Harmonie workstation is a ... processing loads, high quality video capability, and ... recording and review functions A framework that ... and archiving of data A centralized database ...
... features is the PupilFit software which automatically ... the pupil images, producing accurate, repeatable measurements ... circle is shown as a dotted line ... measurement ismeaningful, and not just a number ...
Dual-sided, Interhemispheric Grid Electrode with 16 Contact Leads; Cortical Grid Electrode with 16 Contact Leads; Pediatric Grid Electrode with Flex Connector, 0.5 cm spacing...
Medicine Products: